WASHINGTON, Nov. 5, 2026 /PRNewswire / -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended September 30, 2026.
Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "As health plan customers seek to balance affordability with patient and doctor experience, they continue to turn to Evolent by renewing agreements and in many cases, expanding the work they do with us. That growth and demand from existing clients, as well as strong execution in our 2026 oncology launches, continue to drive strong performance in 2026. Looking ahead, I believe our innovative AI platform and our oncology solution will drive growth and margin expansion for Evolent in the quarters to come."
Highlights include (in thousands, except for average PMPM fees and revenue per case):
| For the Three Months Ended September 30, | |||
| 2026 | 2025 | ||
| Financial Results: | |||
| Revenue | $ 725,367 | $ 479,533 | |
| Net loss attributable to common shareholders of Evolent Health, Inc. | $ (23,566) | $ (26,930) | |
| Net loss margin | (3.2) % | (5.6) % | |
| Adjusted EBITDA | $ 34,257 | $ 38,955 | |
| Adjusted EBITDA Margin | 4.7 % | 8.1 % | |
| Average Lives on Platform/Cases | |||
| Performance Suite | 7,195 | 6,474 | |
| Specialty Technology and Services Suite | 74,733 | 78,050 | |
| Administrative Services | 1,163 | 1,222 | |
| Cases | 11 | 13 | |
| Average Unique Members | 39,804 | 40,781 | |
| Average PMPM Fees/ Revenue per Case | |||
| Performance Suite | $ 26.14 | $ 14.77 | |
| Specialty Technology and Services Suite | 0.32 | 0.40 | |
| Administrative Services | 13.84 | 15.77 | |
| Cases | 3,605 | 3,236 | |
| Medical Expense Ratio | 93.0 % | 85.0 % | |
| Medical Expense Ratio excluding Evolent Care Partners | N/A | 91.9 % |
The rising medical costs impacting health plans continue to drive robust demand for Evolent's complex specialty care solutions.
Evolent announced one renewal and two new revenue agreements, bringing the year-to-date total to seven:
-
First, we renewed our largest Surgical Management customer contract for an additional four years. Surgical Management is the IPG business acquired by Evolent in 2022. We believe this multi-year commitment from a long-standing partner reinforces the value of our model and the strength of our client relationships.
-
Second, we are expanding our relationship with an existing client to provide oncology services across several additional states, representing approximately 1 million Commercial lives, with a January 1, 2027 go-live. The agreement also adds Member Navigation across all existing and new lives, broadening the relationship beyond the client's existing solution and demonstrating our opportunity to drive growth through expanded adoption of Evolent's solutions.
-
Third, we expanded our relationship with a national payer in Specialty Technology & Services for oncology across 11 additional states.
Financial Results of Evolent Health, Inc.
In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we may use or discuss financial measures not prepared in accordance with generally accepted accounting principles ("GAAP"). Definitions of the non-GAAP financial measures as well as reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are presented herein. See "Non-GAAP Financial Measures" for more information.
Reported Results
Evolent Health, Inc. reported the following results in accordance with GAAP (dollars in thousands, except for per share data):
| For the Three Months Ended September 30, | |||
| 2026 | 2025 | ||
| Revenue | $ 725,367 | $ 479,533 | |
| Cost of revenue | 636,946 | 379,759 | |
| Selling, general and administrative expenses | 73,116 | 77,592 | |
| Net loss attributable to common shareholders of Evolent Health, Inc. | (23,566) | (26,930) | |
| Net loss margin | (3.2) % | (5.6) % | |
| Loss per share attributable to common shareholders of Evolent Health, Inc. | |||
| Basic and diluted | $ (0.21) | $ (0.24) |
Total cash and cash equivalents was $148.3 million as of September 30, 2026.
Adjusted Results
Evolent Health, Inc. reported the following adjusted results (dollars in thousands, except for per share data):
| For the Three Months Ended September 30, | |||
| 2026 | 2025 | ||
| Adjusted cost of revenue | $ 635,107 | $ 378,518 | |
| Adjusted selling, general and administrative expenses | $ 56,003 | $ 62,060 | |
| Adjusted EBITDA | $ 34,257 | $ 38,955 | |
| Adjusted EBITDA margin | 4.7 % | 8.1 % | |
| Adjusted income attributable to common shareholders | $ 7,296 | $ 5,630 | |
| Adjusted income per share attributable to common shareholders: | |||
| Basic and diluted | $ 0.06 | $ 0.05 |
Business Outlook
The Company does not believe it can meaningfully reconcile guidance for non-GAAP Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. because the Company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to transactions and other events. Such items may, from time to time, include change in tax receivable agreement liability, other refinancing fees, income (loss) from equity method investees, gain (loss) on repayment/extinguishment of debt, other income (expense), gain (loss) on disposal of non-strategic assets, goodwill impairments, right-of-use asset impairments, gain (loss) on lease terminations, stock-based compensation expense, severance costs and transaction-related costs. Such adjustments may be affected by changes in ongoing assumptions, judgments, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments is not currently determinable but may be significant.
Full Year 2026 Guidance
Incorporating its year-to-date performance, the Company is reiterating its 2026 revenue guidance range to $2.6 billion to $2.7 billion and raising its Adjusted EBITDA range to $130.0 million to $135.0 million.
Additional Outlook Information
The Company expects to deploy $26 million to $28 million in cash for capitalized expenditures during 2026.
This "Business Outlook" section contains forward-looking statements, and actual results may differ materially. Factors that may cause actual results to differ materially from our current expectations in addition to those set forth above are set forth below in "Forward Looking Statements - Cautionary Language" and Evolent Health, Inc.'s filings with the Securities and Exchange Commission ("SEC").
Web and Conference Call Information
Evolent Health, Inc. will hold a conference call to discuss its financial performance and related matters this morning, November 5, 2026, at 8:30 a.m., Eastern Time. To listen to a live broadcast via the internet and view the accompanying materials, please visit the Company's Investor Relations website at http://ir.evolent.com . To participate by telephone, dial (855) 940-9467, or (412) 317-6034 for international callers, and ask to join the "Evolent Health call." Participants are advised to dial in at least fifteen minutes prior to the call to register. An audio playback of the conference call will be available on Evolent's investor relations website for 90 days after the call. Evolent invites all interested parties to attend the conference call.

About Evolent
Evolent specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolent.com.



